Author Archives: Forest Ray PhD

Vilobelimab Safe, Well-tolerated in Phase 2 IXPLORE Study

Adding vilobelimab (IFX-1) to standard of care treatment is safe and well-tolerated among patients with ANCA-associated vasculitis (AAV), according to top-line results from the ongoing Phase 2 IXPLORE study. Some participants also showed clinical response and remission, although the study was not designed to assess the statistical significance…

AAV Transplant Recipients More Often Die With Functioning Kidney

Kidney transplant recipients, whose kidney failure stemmed from ANCA-associated vasculitis (AAV), have less risk of disease recurrence but a higher risk of dying with a functioning transplant,  a recent study suggests. These patients also had a higher risk of dying from complications due to immunosuppression and infection. The study,…